Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
18.36
+0.07 (0.38%)
May 14, 2025, 10:08 AM - Market open
Rigel Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 203.08 | 179.28 | 115.78 | 115.74 | 138.74 | 108.62 | Upgrade
|
| Other Revenue | - | - | 0.1 | - | - | - | Upgrade
|
| Revenue | 203.08 | 179.28 | 115.88 | 115.74 | 138.74 | 108.62 | Upgrade
|
| Revenue Growth (YoY) | 70.16% | 54.71% | 0.12% | -16.57% | 27.73% | 83.21% | Upgrade
|
| Cost of Revenue | 46.82 | 42.03 | 31.63 | 62.02 | 66.32 | 61 | Upgrade
|
| Gross Profit | 156.26 | 137.25 | 84.25 | 53.72 | 72.42 | 47.63 | Upgrade
|
| Selling, General & Admin | 112.33 | 113.06 | 105.74 | 112.45 | 91.89 | 76.6 | Upgrade
|
| Operating Expenses | 112.33 | 113.06 | 105.74 | 112.45 | 91.89 | 76.6 | Upgrade
|
| Operating Income | 43.93 | 24.19 | -21.49 | -58.73 | -19.48 | -28.97 | Upgrade
|
| Interest Expense | -7.9 | -7.92 | -6.87 | -3.71 | -4.86 | -1.35 | Upgrade
|
| Interest & Investment Income | 2.09 | 2.09 | 2.27 | 0.68 | 0.05 | 0.58 | Upgrade
|
| EBT Excluding Unusual Items | 38.12 | 18.37 | -26.09 | -61.75 | -24.29 | -29.74 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -1.32 | -3.52 | - | Upgrade
|
| Other Unusual Items | - | - | 1 | 4.5 | 10.5 | - | Upgrade
|
| Pretax Income | 38.12 | 18.37 | -25.09 | -58.57 | -17.31 | -29.74 | Upgrade
|
| Income Tax Expense | 0.95 | 0.88 | - | - | 0.61 | - | Upgrade
|
| Net Income | 37.18 | 17.49 | -25.09 | -58.57 | -17.91 | -29.74 | Upgrade
|
| Net Income to Common | 37.18 | 17.49 | -25.09 | -58.57 | -17.91 | -29.74 | Upgrade
|
| Shares Outstanding (Basic) | 18 | 18 | 17 | 17 | 17 | 17 | Upgrade
|
| Shares Outstanding (Diluted) | 18 | 18 | 17 | 17 | 17 | 17 | Upgrade
|
| Shares Change (YoY) | 2.34% | 1.64% | 2.07% | -0.00% | 1.03% | 0.81% | Upgrade
|
| EPS (Basic) | 2.11 | 0.99 | -1.44 | -3.44 | -1.05 | -1.76 | Upgrade
|
| EPS (Diluted) | 2.08 | 0.99 | -1.44 | -3.44 | -1.05 | -1.76 | Upgrade
|
| Free Cash Flow | 35.56 | 31.44 | -5.74 | -74.21 | 5.25 | -53.45 | Upgrade
|
| Free Cash Flow Per Share | 1.99 | 1.78 | -0.33 | -4.35 | 0.31 | -3.17 | Upgrade
|
| Gross Margin | 76.94% | 76.56% | 72.70% | 46.41% | 52.20% | 43.84% | Upgrade
|
| Operating Margin | 21.63% | 13.49% | -18.55% | -50.74% | -14.04% | -26.67% | Upgrade
|
| Profit Margin | 18.31% | 9.75% | -21.65% | -50.61% | -12.91% | -27.38% | Upgrade
|
| Free Cash Flow Margin | 17.51% | 17.53% | -4.96% | -64.11% | 3.79% | -49.20% | Upgrade
|
| EBITDA | 46.36 | 26.42 | -20.25 | -57.73 | -18.31 | -28.27 | Upgrade
|
| EBITDA Margin | 22.83% | 14.74% | -17.48% | -49.88% | -13.20% | -26.02% | Upgrade
|
| D&A For EBITDA | 2.43 | 2.23 | 1.24 | 1 | 1.16 | 0.71 | Upgrade
|
| EBIT | 43.93 | 24.19 | -21.49 | -58.73 | -19.48 | -28.97 | Upgrade
|
| EBIT Margin | 21.63% | 13.49% | -18.55% | -50.74% | -14.04% | -26.67% | Upgrade
|
| Effective Tax Rate | 2.48% | 4.80% | - | - | - | - | Upgrade
|
| Revenue as Reported | 203.08 | 179.28 | 116.88 | 120.24 | 149.24 | 108.62 | Upgrade
|
Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.